Global Medical REIT (GMRE) AI Stock Analysis

• Market Cap: $515.55M
• Dividend Yield: 11.01%
• Average Volume (3M): 157.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: 2.73%
• EPS Growth: -131.16%
• Country: US
• Employees: 26
• Sector: Real Estate
• Sector Strength: 53
• Industry: REIT - Healthcare Facilities
• EPS (TTM): -0.45
• Shares Outstanding: 13,407,358
• 10 Day Avg. Volume: 142,959
• 30 Day Avg. Volume: 157,671
• PEG Ratio: -0.16
• Price to Book (P/B): 0.19
• Price to Sales (P/S): 0.74
• P/FCF Ratio: -4.06
• Enterprise Value/Market Cap: 2.45
• Enterprise Value/Revenue: 8.55
• Enterprise Value/Gross Profit: 12.43
• Enterprise Value/Ebitda: 15.21
• 1Y Price Target: $40.70
• Price Target Upside: 14.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 0.12
• Revenue Forecast (FY): $146.47M

• Rating: 55 Neutral
• Price Target: $34.00 ▼(-4.01% Downside)

Global Medical REIT's overall score reflects significant financial challenges, particularly in profitability and cash flow, despite some positive developments in debt management and leasing activities. The high dividend yield and recent strategic initiatives provide some support, but the negative P/E ratio and profitability issues weigh heavily on the score.

Positive Factors

Strong Leasing and Occupancy

High occupancy rates indicate strong demand for GMRE's properties, ensuring stable rental income and reducing vacancy risks, which supports long-term revenue stability.

Debt Maturity Management

Extending debt maturities enhances financial flexibility and reduces refinancing risk, allowing GMRE to focus on strategic growth initiatives without immediate debt pressure.

Preferred Stock Offering

The preferred stock offering strengthens GMRE's financial structure, providing additional capital for operations and potential growth opportunities, enhancing long-term stability.

Negative Factors

Profitability Challenges

Negative profit margins highlight operational inefficiencies, which could hinder GMRE's ability to generate sustainable profits and affect long-term financial health.

Cash Flow Decline

Declining cash flow limits GMRE's ability to reinvest in properties and manage debt, potentially impacting long-term growth and financial resilience.

High Payout Ratio

A high payout ratio limits financial flexibility and could constrain GMRE's ability to invest in growth opportunities, posing a risk to future dividend sustainability.

Global Medical REIT Business Overview & Revenue Model

Company Description

Global Medical REIT Inc. is net-lease medical office REIT that acquires purpose-built specialized healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share.

How the Company Makes Money

Global Medical REIT generates revenue primarily through long-term leases with healthcare operators. The company acquires properties that are typically leased on a triple-net basis, meaning that tenants are responsible for property taxes, insurance, and maintenance costs, which minimizes the operating expenses for GMRE. This structure allows GMRE to earn rental income that is largely predictable and stable. Additionally, GMRE may benefit from property appreciation and increased rental rates over time as demand for healthcare services grows. Strategic partnerships with healthcare providers can also enhance its portfolio by acquiring high-quality properties that are well-positioned in the market, contributing to both occupancy rates and rental income.

Global Medical REIT Financial Statement Overview

Summary

Global Medical REIT faces profitability and cash flow challenges despite moderate revenue growth. The company has managed to reduce leverage, but negative net profit margins and declining cash flow metrics suggest operational inefficiencies and financial instability.

Income Statement

The income statement shows moderate revenue growth with a 4.51% increase in TTM. However, the net profit margin is negative at -1.29%, indicating profitability challenges. Gross profit margin has decreased significantly from previous years, suggesting increased cost pressures. EBIT and EBITDA margins have also declined, reflecting reduced operational efficiency.

Balance Sheet

The balance sheet reveals a stable equity ratio, but the debt-to-equity ratio has improved to 1.50, indicating a reduction in leverage. Return on equity is negative, highlighting profitability issues. The company maintains a reasonable equity ratio, suggesting a balanced asset structure.

Cash Flow

Cash flow analysis shows a significant decline in free cash flow growth, with a negative growth rate of -135.51% in TTM. The operating cash flow to net income ratio is not calculable due to negative net income, and free cash flow to net income ratio is negative, indicating cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	147.99M	138.41M	140.93M	137.17M	115.80M	93.52M
Gross Profit	101.76M	109.16M	112.85M	111.98M	100.32M	82.65M
EBITDA	83.19M	91.47M	111.64M	102.89M	85.35M	53.00M
Net Income	2.50M	6.63M	20.61M	19.14M	17.62M	-1.93M
Balance Sheet
Total Assets	1.27B	1.26B	1.27B	1.39B	1.26B	1.10B
Cash, Cash Equivalents and Short-Term Investments	7.12M	6.82M	1.28M	4.02M	7.21M	5.51M
Total Debt	728.66M	653.59M	624.19M	704.65M	579.86M	607.62M
Total Liabilities	767.41M	700.57M	661.89M	744.20M	625.91M	643.15M
Stockholders Equity	485.29M	534.13M	583.58M	632.98M	622.78M	444.81M
Cash Flow
Free Cash Flow	18.63M	-25.07M	58.39M	-79.66M	-132.69M	-184.27M
Operating Cash Flow	72.50M	70.05M	68.44M	76.54M	68.97M	34.52M
Investing Cash Flow	-86.67M	-45.94M	67.62M	-137.25M	-194.66M	-223.67M
Financing Cash Flow	16.23M	-21.89M	-143.79M	62.41M	127.70M	192.72M

Global Medical REIT Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 35.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GMRE, the sentiment is Positive. The current price of 35.42 is above the 20-day moving average (MA) of 33.28, above the 50-day MA of 32.31, and above the 200-day MA of 34.29, indicating a bullish trend. The MACD of 0.78 indicates Negative momentum. The RSI at 67.51 is Neutral, neither overbought nor oversold. The STOCH value of 84.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GMRE.

Global Medical REIT Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STRW	74 Outperform	$171.61M	21.07	52.29%	4.57%	29.76%	22.76%
UHT	69 Neutral	$579.36M	32.24	10.55%	7.14%	0.68%	-1.34%
SILA	68 Neutral	$1.30B	33.32	2.77%	6.92%	3.74%	77.82%
CHCT	66 Neutral	$440.74M	-39.56	-2.32%	12.17%	3.40%	-240.85%
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
DHC	58 Neutral	$1.17B	-3.29	-18.84%	0.81%	4.10%	8.96%
GMRE	55 Neutral	$515.55M	-142.94	0.49%	11.01%	2.73%	-131.16%

Global Medical REIT Corporate Events

Global Medical REIT Director Ronald Marston to Retire

On December 3, 2025, Ronald Marston announced his intention to retire as a director of Global Medical REIT Inc., effective at the company’s 2026 Annual Meeting of Stockholders. His retirement is not due to any disagreements with the company’s operations or policies, marking a planned transition in the board’s composition.

Global Medical REIT Announces Preferred Stock Offering

On November 13, 2025, Global Medical REIT Inc. and its operating partnership entered into an Underwriting Agreement with several underwriters for the issuance and sale of 2,000,000 shares of its 8.00% Series B cumulative redeemable preferred stock, with an option for an additional 300,000 shares. The offering is expected to close on November 20, 2025, with proceeds intended to be contributed to the operating partnership. Additionally, the company amended its Agreement of Limited Partnership to accommodate the issuance of Series B Preferred Units, mirroring the terms of the preferred stock. This strategic move is aimed at strengthening the company’s financial structure and enhancing its market position.

Global Medical REIT Reports Q3 2025 Net Loss

On November 4, 2025, Global Medical REIT Inc. reported a net loss of approximately $6.0 million for the third quarter of 2025, a significant decline from the net income of $1.8 million in the same period the previous year. The company’s portfolio, as of September 30, 2025, was 95.2% occupied, with a weighted average lease term of 5.3 years, indicating stable occupancy levels despite the financial loss, which could impact investor confidence and the company’s market positioning.

Global Medical REIT Announces Amended Credit Facility

On October 8, 2025, Global Medical REIT Inc. announced a third amended and restated credit facility with JPMorgan Chase Bank, extending the maturity dates of its $400 million revolver and $350 million term loan, now divided into three tranches maturing between 2029 and 2031. The amendment removes a previous credit spread adjustment and maintains the pricing grid and $500 million accordion feature, resulting in an increased weighted average debt term from 1.3 years to 4.4 years, potentially enhancing the company’s financial stability and operational flexibility.

Global Medical REIT Announces Reverse Stock Split

On September 18, 2025, Global Medical REIT Inc. implemented a one-for-five reverse stock split, reducing its authorized common stock from 500 million to 100 million shares. This adjustment, effective September 19, 2025, did not affect the company’s preferred stock or shareholders’ ownership percentages, except for minor changes due to fractional shares being settled in cash. The common stock will trade on a split-adjusted basis on the NYSE from September 22, 2025.